Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer [Yahoo! Finance]
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality [Yahoo! Finance]
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $111.00 to $109.00. They now have a "buy" rating on the stock.